Last reviewed · How we verify
Ammoxetine Hydrochloride Enteric-coated Tablets
Ammoxetine Hydrochloride Enteric-coated Tablets is a norepinephrine reuptake inhibitor Small molecule drug developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. It is currently in Phase 2 development for Attention deficit hyperactivity disorder (ADHD). Also known as: Ammoxetine.
Ammoxetine hydrochloride is a norepinephrine reuptake inhibitor.
Ammoxetine hydrochloride is a norepinephrine reuptake inhibitor. Used for Attention deficit hyperactivity disorder (ADHD).
At a glance
| Generic name | Ammoxetine Hydrochloride Enteric-coated Tablets |
|---|---|
| Also known as | Ammoxetine |
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Drug class | norepinephrine reuptake inhibitor |
| Target | norepinephrine transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 2 |
Mechanism of action
It works by increasing the levels of norepinephrine in the brain, which can help improve symptoms of attention deficit hyperactivity disorder (ADHD).
Approved indications
- Attention deficit hyperactivity disorder (ADHD)
Common side effects
- Nausea
- Headache
- Fatigue
- Insomnia
Key clinical trials
- The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression (PHASE3)
- The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression (PHASE2)
- Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression (PHASE2)
- Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subject (PHASE1)
- Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ammoxetine Hydrochloride Enteric-coated Tablets CI brief — competitive landscape report
- Ammoxetine Hydrochloride Enteric-coated Tablets updates RSS · CI watch RSS
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. portfolio CI
Frequently asked questions about Ammoxetine Hydrochloride Enteric-coated Tablets
What is Ammoxetine Hydrochloride Enteric-coated Tablets?
How does Ammoxetine Hydrochloride Enteric-coated Tablets work?
What is Ammoxetine Hydrochloride Enteric-coated Tablets used for?
Who makes Ammoxetine Hydrochloride Enteric-coated Tablets?
Is Ammoxetine Hydrochloride Enteric-coated Tablets also known as anything else?
What drug class is Ammoxetine Hydrochloride Enteric-coated Tablets in?
What development phase is Ammoxetine Hydrochloride Enteric-coated Tablets in?
What are the side effects of Ammoxetine Hydrochloride Enteric-coated Tablets?
What does Ammoxetine Hydrochloride Enteric-coated Tablets target?
Related
- Drug class: All norepinephrine reuptake inhibitor drugs
- Target: All drugs targeting norepinephrine transporter
- Manufacturer: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Psychiatry
- Indication: Drugs for Attention deficit hyperactivity disorder (ADHD)
- Also known as: Ammoxetine
- Compare: Ammoxetine Hydrochloride Enteric-coated Tablets vs similar drugs
- Pricing: Ammoxetine Hydrochloride Enteric-coated Tablets cost, discount & access